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Background
Cognitive impairment (CI) is known to be present in 
all stages of multiple sclerosis (MS); however, the 
prevalence estimates vary considerably between stud-
ies, ranging from 40% to 65%.1 The profile of CI in the 
overall MS population is now relatively well known, 
involving mainly complex attention, information pro-
cessing speed, episodic memory, and executive func-
tions.1,2 Therefore, brief neuropsychological batteries 
for MS3 and newly developed assessment tools4 
mainly focus on the assessment of these functions. 
However, few studies investigated the differences in 
the prevalence and profile of CI between the different 
MS disease subtypes, providing heterogeneous 
results.5–9 Many of these studies included small clini-
cal samples and focused mainly on relapsing remitting 
(RR) or progressive forms. Moreover, the association 
of CI with several clinical features, such as physical 
disability, sex, and disease duration, is not well estab-
lished, since inconsistent results have been reported in 
the literature.10–13 The heterogeneity of the published 
literature could be, at least in part, attributable to small 
sample size and dissimilarities in the clinical charac-
teristics of the studies’ samples. Exploring the inde-
pendent effects of age, physical disability, disease 
duration, and disease subtype could prove central to 
provide a better understanding of the potential role and 
interaction of cognitive reserve, brain aging, and dis-
ease severity for determining CI in MS.
The aims of this collaborative, nationwide, cross- 
sectional study were to describe the prevalence and 
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Background: There is limited and inconsistent information on the clinical determinants of cognitive 
impairment (CI) in multiple sclerosis (MS).
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in SP and primary progressive multiple sclerosis (PPMS) than in CIS and RR. In multivariable logistic 
regression analysis, the presence of CI was significantly associated with higher Expanded Disability 
Status Scale (EDSS) and older age.
Conclusion: CI is present in all MS subtypes since the clinical onset and its frequency is increased in the 
progressive forms, but these differences seem to be more associated with patient age and physical dis-
ability than to disease subtype per se.
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profile of CI in a large sample of patients with MS, 
with a specific focus on prevalence and neuropsycho-
logical profiles across different disease subtypes, and 
to assess the association between CI and the main 
demographic and clinical features.
Methods
Study design and setting
We invited all consecutive MS patients attending their 
regular clinical follow-up visits in six Italian MS 
Centres during the study period (January–October 
2010) to participate in the study. The inclusion criteria 
were (a) diagnosis of MS based on the 2001 McDonald 
criteria14 and (b) being between 18 and 70 years old. 
The exclusion criteria were as follows: (a) presence of 
current or past neurological disorder other than MS; 
(b) active major psychiatric illness (such as schizo-
phrenia, bipolar disorder, and major depressive disor-
der); (c) history of learning disability; serious head 
trauma, alcohol or drug abuse; and (d) relapse and/or 
corticosteroid use within 4 weeks preceding the neu-
ropsychological assessment. The classification of dis-
ease subtypes was based on the 1996 Lublin’s 
definition.15 All the participants provided informed 
consent and the study was approved by the ethics 
committees of the different institutions.
Clinical and neuropsychological assessment
Patient data were collected using a common data-
base shared among the participating centers and 
included disease course, age at onset, disease dura-
tion, relapses in the previous year, current treatment 
with disease modifying drugs, and education (com-
plete years of formal schooling). Physical disability 
was assessed using the Expanded Disability Status 
Scale (EDSS),16 a scale validated to monitor disease 
progression in MS.17 Fatigue was assessed using the 
fatigue severity scale (FSS), a scale developed and 
validated for MS18 that is composed of nine items 
with a score range of 9–63. Depression was assessed 
using the Montgomery and Asberg Depression Scale 
(MADRS), a standardized measure of mood disor-
der, with scores ranging from 0 to 60.19 The FSS and 
MADRS scales were not part of the initial study pro-
tocol; nevertheless, they were routinely used in sev-
eral of the study centers, resulting in FSS being 
applied in 728/1040 and MADRS in 356/1040 
patients at the time of the study assessment.
A neuropsychological evaluation was performed 
using the Brief Repeatable Battery (BRB)3 and the 
Stroop test.20 The BRB incorporates tests of verbal 
memory acquisition and delayed recall (Selective 
Reminding Test (SRT)); visual memory acquisition 
and delayed recall (10/36 Spatial Recall Test 
(SPART)); attention, concentration, and speed of 
information processing (Paced Auditory Serial 
Addition Test (PASAT); Symbol Digit Modalities 
Test (SDMT)); and verbal fluency on semantic stimu-
lus (Word List Generation (WLG)). The neuropsy-
chologists involved in the study had participated in a 
common training session in which test administration 
and scoring procedures had been clarified and agreed 
upon. Test failure was defined as a score below the 
5th or above the 95th percentile, when appropriate, 
according to age, sex, and education-adjusted Italian 
norms.21 Impairment in a given cognitive domain was 
defined as failure in at least one test assessing that 
domain, namely, SRT for Verbal Learning, SPART for 
Visuospatial Learning, SDMT and PASAT for 
Information Processing Speed, and WLG and the 
Stroop tests for Executive Function. CI was defined 
as impairment in at least two cognitive domains.
Statistical analysis
Group comparisons were performed using Student’s 
t-test for independent samples, the non-parametric 
Kruskal–Wallis test or χ2 test with z-test adjusted for 
multiple comparisons (Bonferroni method), where 
appropriate. The tests were two-sided, with a signifi-
cance level of 0.05. To confirm the theoretical cogni-
tive domains assessed by the cognitive tests, we 
performed principal component analysis.
To measure the association between the presence of 
CI and the different clinical and demographic varia-
bles, we calculated crude and adjusted odds ratio 
(OR), using simple and multivariate logistic regres-
sion. We built an a priori model (Model 1), including 
the demographic variables and education, and esti-
mated the adjusted OR of the other variables. In 
Model 2, we adjusted to all variables that in Model 1 
had a p-value lower that 0.1. Finally, we fitted in 
Model 3 the two variables that remained significant in 
Model 2 (age and EDSS), and estimated the adjusted 
OR of the other main clinical variables (disease dura-
tion and clinical course). We also assessed the pres-
ence of interactions between the variables in Model 2 
and Model 3, and tested the inclusion of quadratic 
factors for each continuous variable, to check the 
presence of a non-linear relation between the inde-
pendent variables and the log odds. The presence of 
multi-collinearity was assessed by calculating the cor-
relation matrix between the main variables, and the 
variance-inflation (VIF) and generalized variance-
inflation factors (GVIF) for logistic regression. The 
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goodness of fit of the models was assessed using the 
Hosmer–Lemeshow test and the discrimination power 
was using the C-statistic. The same steps were repli-
cated to fit logistic regression models for impairment 
in each cognitive domain (final models shown). 
Statistical analysis was performed using IBM SPSS 
Statistics Version 23.0.
Results
The study sample consisted of 1040 patients, 167 
clinically isolated syndrome (CIS), 759 RR, 74 sec-
ondary progressive (SP) and 40 primary progressive 
(PP) MS patients. The main demographic and clinical 
characteristics of the sample are depicted in Table 1. 
The refusal rate in the largest study center (Florence) 
was 14.5%. Although exact records of refusals are not 
available for the other centers, the feedback was that 
the vast majority of the patients agreed to participate.
In the principal component analysis of the items from 
the neuropsychological evaluation, the variance 
explained by the four retained components was 69% 
(Supplementary Table 1). For component 1 (23% var-
iance), the items with a high factor loading corre-
sponded to SRT test; for component 2 (17% variance), 
to the PASAT test; for component 3 (15% variance), 
to the WLG and Stroop tests; and for component 4 
(14% variance), to the SPART test (Supplementary 
Table 1), while that of the SDMT presented a moder-
ate loading factor for both components 2 (0.44) and 3 
(0.59). These components corresponded approxi-
mately with the theoretical cognitive domains: com-
ponent 1 to verbal learning, component 2 to 
information processing speed, component 3 to execu-
tive function, and component 4 to visuospatial learn-
ing; based on these results and on the previous 
literature, we retained the theoretical construct for the 
cognitive domains, including the SDMT in the infor-
mation processing speed domain.
In the whole study sample, the prevalence of CI was 
46.3%; 34.5% in CIS, 44.5% in RR MS, 79.4% in SP, 
and 91.3% in patients with PP. The differences in 
prevalence were statistically significant in the com-
parisons of CIS versus SP, CIS versus PP, RR versus 
SP, and RR versus PP (p < 0.001) (Table 2). Overall, 
information processing speed was the most com-
monly affected cognitive domain (47.9%). There 
were no significant differences between patients with 
CIS and RR regarding the frequency of impairment in 
the different domains (Table 2). On the whole, in 
patients with SP and PP courses, the presence of CI, as 
well as impairment on different cognitive domains, 
was approximately twofold increased when compared 
to CIS and RR (Table 2). There were no significant 
differences between the prevalence of impairment by 
domain between SP and PP patients.
Considering the whole sample, patients with CI were 
older, had a longer disease duration, higher disability 
levels on the EDSS, and an older age at MS onset. 
Table 1. Clinical and demographic characteristics of the study patients.
Total sample 
(n = 1040)
CIS (n = 167) RR (n = 759) SP (n = 74) PP (n = 40) p-value
Age, mean (SD) (years) 40.1 (11.0) 33.9 (9.8) 39.9 (10.2) 51.6 (9.5) 49.3 (10.9) <0.001a,b
Sex (female), n (%) 704 (67.7) 111 (66.5) 529 (69.7) 43 (58.1) 21 (52.3) 0.062
Education, mean (SD) (years) 12.2 (3.7) 12.7 (3.3) 12.3 (3.7) 11.0 (4.1) 10.2 (3.4) <0.001a,c
Age at onset, mean (SD) (years) 29.7 (9.8) 32.5 (9.4) 28.6 (9.4) 32.2 (11.1) 36.4 (10.7) <0.001d
Disease duration, mean (SD) (years) 10.3 (9.1) 1.4 (2.2) 11.2 (8.4) 19.4 (10.0) 12.8 (6.7) <0.001a,e,f
Relapses in the previous year, mean (SD) 0.9 (1.0) 1.0 (0.5) 0.9 (1.1) 0.3 (0.6) 0.0 (0.0) <0.001b,g
EDSS, median (IQR) 0.2 (2.5; 3.5) 1.5 (1.0; 2.0) 2.0 (1.5; 3.5) 6.0 (4.5; 6.5) 5.25 (5.0; 6.0) <0.001a,b
Treatment with DMDs, n (%) 658 (62.7) 28 (16.8) 571 (75.2) 41 (55.4) 9 (22.5) <0.001d,h
CIS: clinically isolated syndrome; RR: relapsing remitting; SP: secondary progressive; PP: primary progressive; SD: standard deviation; EDSS: Expanded 
Disability Status Scale; IQR: interquartile range; DMDs: disease modifying drugs.
Superscript letters denote significant differences between groups, adjusted for multiple comparisons with the Bonferroni method (adjusted p-value = 0.008):
aCIS versus RR, SP, and PP.
bRR versus SP and PP.
cRR versus PP.
dRR versus CIS, SP, and PP.
eRR versus SP.
fSP versus PP.
gPP versus CIS and SP.
hSP versus RR, CIS, and PP.
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There were no significant differences in sex, educa-
tion, and relapses in the previous year between cogni-
tively preserved and impaired patients (Table 3).
In the univariate logistic regression, there was a signifi-
cant association between the presence of CI and older 
age (OR (10 years) = 1.75; p < 0.001), longer disease 
duration (OR (10 years) = 1.68; p < 0.001), and higher 
disability levels on the EDSS (OR (2 points) = 1.99; 
p < 0.001). There were no significant differences 
regarding sex (OR = 1.08; p = 0.59), education 
(OR = 0.97; p = 0.12), and clinical disease activity 
(OR = 0.76; p = 0.05). In the subset of patients with 
fatigue data (n = 728), there was a significant associa-
tion between higher FSS score and CI (OR (5 
points) = 1.05; p = 0.03), while in the subset with 
depression data (n = 356), no association was found 
between the MADRS score and CI (OR (5 points) = 1.02; 
p = 0.07). When adjusting for the effect of the 
demographic variables in the a priori model, disease 
duration, EDSS, clinical course, and relapses in the 
previous year presented an association of p < 0.1 and 
were fitted in Model 2. In this model, the presence of 
CI was significantly associated only with older patient 
age, while the association with other variables was 
non-significant (Table 4). When adjusting the OR of 
disease duration and clinical course to age and EDSS 
(Model 3), the association with CI is non-significant 
(p = 0.47 and p = 0.30, respectively). It is important to 
note the decrease in the OR of disease duration and dis-
ease course when they are fitted in the model with 
EDSS and age, while the OR for these two latter vari-
ables stays approximately the same (Table 4). The VIF 
and GVIF for the variables (Table 4) are well below the 
conservative cut point of 5.0,22 indicating a relatively 
low multi-collinearity. There was no significant effect 
of the quadratic terms of the continuous variables or of 
interaction factors between the variables.
Table 2. Prevalence and profile of cognitive impairment in the study sample.
Total sample 
(n = 1040)
CIS 
(n = 167)
RR 
(n = 759)
SP 
(n = 74)
PP 
(n = 40)
p-value
Cognitive impairment (⩾2 domains) 46.3% 34.5% 44.5% 79.4% 91.3% <0.001a
Verbal learning 31.1% 27.1% 28.7% 57.7% 46.2% <0.001a
Visuospatial learning 20.5% 14.5% 19.9% 35.3% 31.6% <0.001a
Information processing speed 47.9% 41.2% 45.7% 79.4% 66.7% <0.001a
Executive function 40.8% 41.8% 36.2% 76.4% 92.3% <0.001a
Number of impaired domains 
(impaired patients), mean (SD)
2.6 (0.7) 2.7 (0.7) 2.5 (0.7) 2.8 (0.8) 2.5 (0.6)  0.056
Number of impaired domains (all 
patients), mean (SD)
1.4 (1.2) 1.2 (1.2) 1.4 (1.2) 2.4 (1.1) 2.3 (0.7) <0.001a
CIS: clinically isolated syndrome; RR: relapsing remitting; SP: secondary progressive; PP: chronic progressive; SD: standard devia-
tion.
Superscript letters denote significant differences between groups, adjusted for multiple comparisons with the Bonferroni method 
(adjusted p-value = 0.008):
aCIS versus SP; CIS versus PP; RR versus SP; and RR versus PP.
Table 3. Comparison of clinical and demographic characteristics between impaired and non-impaired patients.
Without cognitive 
impairment (n = 486)
With cognitive 
impairment (n = 422)
p-value
Age, mean (SD) (years) 36.9 (9.8) 43.2 (11.2) <0.001
Sex (female), n (%) 334 (68.7%) 283 (67.1%) 0.320
Education, mean (SD) (years) 12.52 (3.3) 12.12 (4.0) 0.109
Age at onset, mean (SD) (years) 28.5 (8.9) 30.7 (10.5) 0.001
Disease duration, mean (SD) (years) 8.4 (7.8) 12.5 (10.0) <0.001
Relapses in the previous year, mean (SD) 0.93 (0.99) 0.82 (0.99) 0.128
EDSS, mean (SD) 2.1 (1.4) 3.0 (1.8) <0.001
Treatment with DMDs, n (%) 289 (59.5%) 266 (63.0%) 0.276
EDSS: Expanded Disability Status Scale; DMDs: disease-modifying drugs; SD: standard deviation.
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Moreover, in an analysis focusing on single cognitive 
domains, both higher physical disability on the EDSS 
and older age were associated with increased preva-
lence of impairment, even after adjusting for the other 
variables of interest (Table 5). Executive function was 
the only cognitive domain in which impairment 
remained associated with disease subtype (Table 5) 
after adjusting for the other variables in the model (PP 
and SP > CIS > RR).
Discussion
In this large, collaborative study, we assessed the cog-
nitive performance of MS patients using a neuropsy-
chological battery specifically developed and 
validated for the disease. Although the study was 
clinic-based rather than population-based, it involved 
the main national MS centers, thus providing a rea-
sonably good representation of the population of MS 
patients in the country.
The prevalence of CI in our study was found to be 
46.3%, a figure in line with what has been reported in 
the recent literature.1,2,8 The overall profile of CI was 
also consistent with what has been described,2 partic-
ularly concerning the frequent impairment in infor-
mation processing speed and episodic memory. 
However, the prevalence of impairment in executive 
function was higher than what has been reported in 
some of the previous literature.1,2 The two tests used 
for assessing aspects of executive functions in this 
study were the Stroop test and the WLG test: notably, 
a component of speed in information processing can-
not be ruled out in these tests. To address this issue, 
we performed principal component analysis to con-
firm the theoretical cognitive domains. We found four 
main components, with the WLG and the Stroop tests 
having a high factor loading for the same component 
(0.78 and 0.66, respectively). Additionally, using 
healthy controls from a previously published norma-
tive sample,21 we performed an exploratory logistic 
regression analysis to determine if the differences in 
the Stroop and WLG scores between patients and con-
trols remained significant after adjusting for the 
SDMT. We found that adjusting for SDMT did not 
change the OR of the associations between these test 
scores and patient status (Stroop: crude OR = 1.32 
(p < 0.001); adjusted OR = 1.23 (p < 0.001); WLG: 
crude OR = 0.31 (p < 0.001); adjusted OR = 0.37 
(p < 0.001)). The results from this analysis indicate 
that the ST and the WLG tests have an ability to dis-
tinguish between patients and controls that is not 
greatly reduced after controlling for the processing 
speed component assessed by the SDMT, suggesting 
they have a potential value in assessing executive 
function in MS. Overall, these findings suggest the 
importance of assessing executive function in patients 
with MS and advocate for an inclusion and further 
evaluation of tools such as the WLG test in future 
studies of CI in MS.
CI was more frequent in patients with RR than CIS 
(44.5% vs 34.5%); however, the difference was not 
statistically significant. Patients with RR and CIS pre-
sented a similar cognitive profile, with a more fre-
quent involvement of information processing speed 
and executive function compared with other cognitive 
domains. In comparison with CIS and RR, the preva-
lence of CI was significantly higher in the progressive 
forms, as was the number of affected cognitive 
domains. Indeed, when compared with patients with 
CIS and RR, our patients with PP and SP had an 
approximately twofold higher prevalence of impair-
ment in the distinct cognitive domains, with no par-
ticular domain disproportionately represented. There 
is some controversy in the literature regarding the 
prevalence of CI in the secondary compared with the 
PP forms, with different authors reporting patients 
with SP as more, equally, or less affected than patients 
with PP.1,5,7 As for the neuropsychological profile, 
efforts to define distinct cognitive profiles between 
SP and PP patients have revealed only subtle, often 
inconsistent, differences.1,5,7 In this study, patients 
with SP and PP presented similar prevalence and pro-
file of CI: several cognitive domains were affected in 
a sizeable proportion of patients, with higher preva-
lence of impairment in information processing speed 
and executive function followed by verbal learning. It 
should be acknowledged, however, that a potential 
under-representation of the PPMS subtype in our 
study population can suggest some selection of study 
participants, since patients with PPMS—for whom no 
disease modifying drugs are available—may be less 
likely referred to specialized MS centers.
In the multivariable analysis, we found that the main 
determinants of overall CI were increased physical 
disability on the EDSS and older patient age, rather 
than disease duration or subtype per se.
Additionally, the multivariable analysis by cognitive 
domain confirmed increased physical disability and 
older age as the two main determinants of impair-
ment, the effect of disease subtype only remaining 
significant in the executive function domain. These 
findings support a prominent effect on cognitive func-
tioning of aging and disease severity, rather than of 
different pathogenetic mechanisms related to each 
disease subtype. It is interesting to note that agreeing 
results have been found in a large single center study, 
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where clustering by disease subtype did not show any 
differences in the cognitive profile of CI.23
Regarding the relation between physical disability 
and CI, there is some heterogeneity in the published 
literature.10–12 The results from this study clearly 
imply an association between increasing degrees of 
physical and cognitive disability, that is also sup-
ported by the few available longitudinal series, with 
smaller sample size.24,25 The observed relationship 
may be an effect of disease severity, progression, and 
biological changes associated with aging, with 
increasing burden of lesions in the brain, atrophy, and 
diffuse changes in the white and gray matter, as 
depicted by imaging and pathological studies.26 A 
recent study has also suggested the existence of iso-
lated cognitive relapses that can be detected only 
through periodic cognitive assessment and may con-
tribute to the burden of CI in the long run.27
The absence of an independent effect of disease dura-
tion in overall CI is another noteworthy finding from 
this study. On one hand, age and disease duration are 
correlated and it may be difficult to disentangle the 
effect of these two variables. However, the correlation 
between patient age and disease duration in this 
patient sample is not particularly strong (r = 0.54; 
Supplementary Table 2), resulting in low multi-collin-
earity between the variables (Table 4). On the other 
hand, it is interesting to note the parallel between our 
cross-sectional cognitive findings and what has been 
reported in large natural history studies on disease 
prognosis, where physical disability and disease pro-
gression are more related to patient age than to the 
duration of the disease or the clinical phenotype at 
onset,28,29 suggesting, as in this study, that disease 
duration is not an accurate predictor of disease pro-
gression. Overall, these results support the hypothesis 
that in MS the shift from a predominantly inflamma-
tory phase, dominated by clinical relapses, to a pre-
dominantly neurodegenerative phase, dominated by 
irreversible progression of neurological disability, 
may be mainly driven by biological factors related to 
aging. Furthermore, the results concur with the 
hypothesis of cognitive reserve, as aging has previ-
ously been associated with decreased plasticity and 
capability of functional reorganization in MS that 
probably results from the interaction between cerebral 
aging and the accumulation of structural brain 
damage.30
As for the role of sex, the published research usually 
points to an overall worse functional prognosis in 
males with MS when compared to females.31 Some 
previous studies have suggested this also applies to 
cognitive outcomes,32 but the issue is controversial 
in the literature, as most recently published large 
series have found no significant differences in the 
prevalence of overall CI.8,12,13,23 In our sample, in 
spite of a higher physical disability level in males, 
we were not able to confirm any significant effect of 
sex in the prevalence of overall CI, neither as a first 
order association nor when adjusting for other pre-
dictors. Nevertheless, sex-related differences were 
found in the verbal learning and executive function 
domains. The better performance of women in ver-
bal learning tests had already been reported, and 
could perhaps contribute to explain the higher preva-
lence of CI in males in some of the published litera-
ture, as tests designed to evaluate executive 
functions, in which females performed worst in this 
study, are not always used to assess patients with 
MS. Nevertheless, the presence of sex-related differ-
ences in some cognitive domains could hint at an 
interaction between sexual hormones, disease activ-
ity, and neurodegeneration, as hypothesized by some 
authors.32
There was also no association of CI with the use of 
disease modifying drugs. This may be accounted for 
by the discontinuation or absence of treatment in the 
older and more disabled patients with the progressive 
phenotypes. It is also possible that patients with RR 
with more active and severe disease are more likely to 
be treated, which renders it difficult to determine the 
impact of disease modifying drugs on cognition. 
Longitudinal, controlled studies are needed to shed 
some light on this score.
As for the association of progressive course and 
higher impairment in executive function, this is 
mainly driven be the Stroop test results. We can spec-
ulate that this relationship is due to increased frontal 
dysfunction33 and frontotemporal lobe atrophy34 in 
patients with progressive forms compared with 
patients with RR. However, the higher impairment in 
executive function found in CIS patients was mainly 
driven by a worse performance on the WLG test, 
which is consistent with findings obtained in a small 
clinical series.8
One limitation of our study is the partial data on 
depression and fatigue that are well-known potential 
confounders for cognitive performance in MS.1 
However, performing a sensitivity analysis in the sub-
sets of patients with available data we found that 
fatigue and depression scores were not retained in the 
multivariable analysis. These results suggest that 
fatigue and depression were not major contributors to 
MS-related CI in these patients.
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The model using age and physical disability alone 
(Model 3) presented an accuracy of 70% to classify 
patients as having CI, implying that there are other 
factors that could explain the remaining variability in 
the subject cognitive outcome, such as genetic deter-
minants, environmental factors, comorbidities, as 
well as different individual resilience to brain damage 
due to intellectual enrichment and cognitive 
reserve.12,35 Indeed, previous studies have found an 
association between CI and measures of cognitive 
reserve, such as the cognitive reserve index,35 which 
is composed of education and an assessment of pre-
morbid IQ and premorbid leisure activities. The use 
of these measures should probably be expanded in 
future studies, as education alone is probably not a 
good enough surrogate of cognitive reserve in many 
populations, as suggested by the results from the pre-
sent and several of the previous studies, which have 
reported no direct association of CI and education.8,13
In conclusion, the findings obtained from this large 
clinical series strongly imply that the presence of CI is 
more related to patient age and disease severity than 
to disease duration or subtype per se. Furthermore, 
this study clearly documents a significant presence of 
CI since the earlier stages of MS, which increases in 
frequency and severity in the progressive stages. It 
also adds evidence to previous clinical studies5–9 and 
therapeutic trials in CIS,36 pointing to the need for 
systematic neuropsychological assessment since the 
beginning of MS and monitoring throughout the dis-
ease course, suggesting that prompt diagnosis and 
management strategies should ideally be pursued at a 
younger patient age, when compensatory abilities, 
brain plasticity, and cognitive reserve may better miti-
gate the effects of pathological damage in the brain.
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